IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells
- 1 September 2009
- journal article
- Published by The American Association of Immunologists
- Vol. 183 (5), 3170-3176
- https://doi.org/10.4049/jimmunol.0803721
Abstract
T memory/effector cells (Tmem/eff) isolated from psoriatic patients are chronically activated and poorly suppressed by regulatory T cells (Treg). The proinflammatory cytokine IL-6, which signals through Stat3, allows escape of Tmem/eff cells from Treg-mediated suppression in a murine system. We show here that IL-6 protein is markedly elevated and most highly expressed by CD31+ endothelial cells and CD11c+ dermal dendritic cells (DCs) in lesional psoriatic skin. We hypothesized that exposure to high IL-6 in lesional tissue may lead to the dampened Treg function observed in psoriasis patients. Indeed, we found that IL-6, but not other Stat3-activating cytokines, was necessary and sufficient to reverse human T cell suppression by Treg in an in vitro model using activated DCs as a source of IL-6. IL-6Rα and gp130 expression was significantly elevated in psoriatic effector T cells compared with normal controls. Overall, IL-6Rα expression on Treg exceeded that of effector T cells, and both populations phosphorylated Stat3 in response to IL-6. Phosphorylation of Stat3 in T cells contributes to Th17 differentiation and we identify cells within lesional tissue that coexpress CD3, IL-17, and IL-6, indicating that Th17 cells are present in vivo within the psoriatic Tmem/eff population and contribute to IL-6-mediated resistance to Treg suppression. Taken together, T lymphocytes trafficking into lesional psoriatic skin encounter high IL-6 from endothelial cells, DCs, and Th17 cells, enabling cutaneous T cell escape from Treg suppression and Th17 participation in inflammation. Targeting IL-6 signaling pathways in psoriasis may rebalance Treg/T effector activity and ameliorate disease.Keywords
This publication has 38 references indexed in Scilit:
- IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitisProceedings of the National Academy of Sciences, 2008
- IL-21 and TGF-β are required for differentiation of human TH17 cellsNature, 2008
- In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORγt+ T cellsThe Journal of Experimental Medicine, 2008
- Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesThe Journal of Experimental Medicine, 2007
- IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cellsProceedings of the National Academy of Sciences, 2007
- Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune diseaseImmunological Reviews, 2006
- Interleukin-6 and its receptor: from bench to bedsideMedical Microbiology and Immunology, 2006
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationThe Journal of Experimental Medicine, 2005
- Increased interleukin-7 levels in the sera of psoriatic patients: lack of correlations with interleukin-6 levels and disease intensityClinical and Experimental Dermatology, 2000
- Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes.JCI Insight, 1995